AMCP CEO Susan Cantrell Comments On Supreme Court Case
In commenting on Rutledge v. The Pharmaceutical Care Management Association, scheduled to be argued before the US Supreme Court yesterday, [...]
Enhancing RWE through Natural History Studies
Deploying RWE-analyses is not just a simple matter of having sufficient statistical knowledge. There are a variety of RWE methodologies [...]
Despite Limitations, Claims Data Still Useful in Fight Against COVID-19
The use of healthcare claims data in studying infectious disease has historically been rather limited. There are many other sources [...]
AMCP 2021’s Call for Poster Abstracts Now Open
AMCP invites submissions for abstracts to be presented at AMCP 2021 in the spring. Don’t miss your chance to share [...]
How Will Innovation Value be Redefined in 2021?
The health policy landscape will most certainly be altered in 2021 as a result of the US Presidential election. No [...]
Personalized Medicine Coalition Takes Aim at Setting Patient-centered Research Agenda
The Personalized Medicine Coalition (PMC) released a new patient-centered research agenda for personalized medicine defining 45 research questions across nine [...]
[Webinar] Cannabis Research to Reinforce Formulary Coverage Decisions
Cannabis as medicine has generated a tremendous amount of interest in the scientific community. It has also generated a tremendous [...]
COVID-19 and Prescription Utilization
The stay-at-home orders and economic uncertainty brought about by COVID-19 has impacted medication adherence and how patients manage their health. [...]
How HEOR Professionals Can Be Force Multipliers in the Fight Against COVID-19
US President Donald Trump and First Lady Melania Trump join the growing ranks of world leaders infected by COVID-19. It [...]
Onshoring Essential Drug Manufacturing is a Matter of National Security
Recently, FDA Commissioner Stephen Hahn and Deputy Commissioner Anand Shah wrote an op-ed stating that the COVID-19 pandemic exposed the [...]
ICER Weighs in on Fair Access to Prescription Drugs
Independent nonprofit Institute for Clinical and Economic Review (ICER) published a new white paper entitled “Cornerstones of ‘Fair’ Drug Coverage: [...]
Good Data Holds Tremendous Value for Patients
Innovative use of good data can lead to better patient care pathways and models of care. Collecting, collating, and assessing [...]
AMCP Partnership Forum: New Specialty Medication Benefit and Reimbursement Designs
One of the biggest challenges facing patients and payers is the rising cost of specialty drugs including gene therapies and [...]
How Government Permits Cross-subsidies to Inflate Healthcare Costs
Government often permits companies to overcharge one set of consumers in order to subsidize other consumers in a market-distorting phenomenon [...]
Syapse and FDA Leverage Real-World Data to Study Impact of COVID-19 on Cancer Patients
According to the National Cancer Institute, the COVID-19 pandemic has resulted in delays for cancer screening, diagnosis, and treatment, leading [...]
[Webinar] The Informative Bayesian: Meta-analytic Predictive (MAP) Priors
Real world data typically has a lot of missing information. This often requires imputation of missing values which is not [...]
Harnessing the Power of RWD in China
In 2018, China made the cultivation of healthcare big data a national priority. Such data represent a tremendous opportunity for [...]
Can Economic Evaluation Achieve Meaningful Use in Reducing Healthcare Costs in the US?
Despite being the most inefficient in terms of healthcare spending among developed nations, the United States does not routinely apply [...]
[Podcast] Co-pay Cards, Co-pay Accumulators, and Co-pay Maximizers
Join president and CEO of AscellaHealth LLC Dea Belazi, PharmD, MPH for a discussion of game theory as he contrasts [...]
Submit Your Abstracts for ASHEcon 2021!
The 10th Annual Conference of the American Society of Health Economists (ASHEcon) to be held at the Marriott Wardman Park [...]
Pharmaceuticals Purchasing: Lessons From Other Countries
Dr. James Robinson of UC Berkeley cautions against the widening gulf and conflict between the increasing prices set by drugmakers [...]
For Shame: Congress Accuses Novartis, Amgen and Mallinckrodt of Price-Gouging
Amgen, Mallinckrodt, and Novartis are now in the same boat as Celgene and Teva. A congressional probe released several reports [...]
MMIT Announces 2020 Directory of Health Plans
Getting accurate payer and health plan enrollment data in a timely fashion is difficult; understanding the impact of health plan [...]
Deomcrats Take Pharma Executives to Task Over Excessive Price Hikes
Pharma industry executives have long justified increasing drug prices by pointing out the costs and risks of research and the [...]
Hospitals and Outpatient Care Are the Primary Drivers of Sky-high US Healthcare Costs
Although drug prices are at the forefront of many voters’ minds, they are not actually the main reason the U.S. [...]